Equity Profile

IRON

Disc Medicine, Inc.

Health CareBiotechnology$2.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare and serious blood disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential to understand how well the company is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare and serious blood disorders. As part of the health care sector, its work is crucial in addressing unmet medical needs and improving patient outcomes in specialized areas of medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q1-2026, Disc Medicine reported an EPS of -$1.65, missing estimates by 6.45%. The stock reacted slightly negatively, declining by 0.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Disc Medicine are mixed, with uncertainty surrounding its ability to meet or exceed prior earnings results. Investors are closely watching how the company addresses its ongoing challenges.

Bull Case

If Disc Medicine can show improved clinical trial results or new partnerships, it could significantly boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide clear guidance, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's history of missing EPS estimates, this figure will be crucial in determining market sentiment.

What updates will management provide regarding ongoing clinical trials?

Investors will be looking for clarity on trial progress and potential future revenue streams, which could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for positive news from ongoing clinical trials, which could lead to a turnaround in sentiment.

Supporting Evidence

The options market is pricing a 22.14% move, indicating high expectations for volatility.

Insider selling may suggest a lack of confidence in near-term performance, contrasting with potential positive trial outcomes.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Disc Medicine can demonstrate progress in its clinical programs and manage costs effectively.

Bull Confirmed If

A narrower EPS loss of -$1.50 or better, indicating improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.75, suggesting ongoing challenges in cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$841,283.01

12,388 sh

2 insiders

Net

$841,283.01

Net selling

Most Active Insiders· 4 open-market trades

Chief Financial OfficerFranchi Jean M.
$460,834.05

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests the stock could rise by approximately 0.64% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses expectations again, history suggests a potential decline of around 0.64%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of clinical trials and expected timelines for results.
2Management's commentary on cost management strategies and operational efficiency.
3Details on any new partnerships or collaborations that could enhance growth.
4Insights into market demand for their products and any competitive developments.
5Guidance on future earnings expectations and strategic priorities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare and serious blood disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential to understand how well the company is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q1-2026, Disc Medicine reported an EPS of -$1.65, missing estimates by 6.45%. The stock reacted slightly negatively, declining by 0.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Disc Medicine can show improved clinical trial results or new partnerships, it could significantly boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide clear guidance, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous estimates?

Given the company's history of missing EPS estimates, this figure will be crucial in determining market sentiment.

What updates will management provide regarding ongoing clinical trials?

Investors will be looking for clarity on trial progress and potential future revenue streams, which could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for positive news from ongoing clinical trials, which could lead to a turnaround in sentiment.

Supporting Evidence

The options market is pricing a 22.14% move, indicating high expectations for volatility.

Insider selling may suggest a lack of confidence in near-term performance, contrasting with potential positive trial outcomes.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Disc Medicine can demonstrate progress in its clinical programs and manage costs effectively.

Bull Confirmed If

A narrower EPS loss of -$1.50 or better, indicating improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.75, suggesting ongoing challenges in cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$841,283.01

12,388 sh

2 insiders

Net

$841,283.01

Net selling

Most Active Insiders· 4 open-market trades

Chief Financial OfficerFranchi Jean M.
$460,834.05

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests the stock could rise by approximately 0.64% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses expectations again, history suggests a potential decline of around 0.64%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of clinical trials and expected timelines for results.
2Management's commentary on cost management strategies and operational efficiency.
3Details on any new partnerships or collaborations that could enhance growth.
4Insights into market demand for their products and any competitive developments.
5Guidance on future earnings expectations and strategic priorities.